This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GROUZMANN, E. Articles by BOHUON, C. Search for Related Content PubMed PubMed Citation Articles by GROUZMANN, E. Articles by BOHUON, C.

Plasma Neuropeptide Y Concentrations in Patients with Neuroendocrine Tumors

Laboratoire d’Immunotoxicologie-UER de Pharmacie (E.G., C.B.) 92296 Chatenay-Malabry, France
Département de Biobgie Clinique-Institut Gustave-Roussy (E.C.) 94805 Villejuif Cedex, France

Address requests for reprints to: E. Comoy, Départment de Biologie Clinique, 94805 Villejuif Cedex, France.

In order to develop an immunoradiometric assay for human neuropeptide (hNPY), a recently discovered and potent vasoconstrictor 36-amino-acid peptide, we used hNPY and some of its subpeptides to prepare monoclonal anti-NPY antibodies. Two monoclonal antibodies with high affinity for hNPY, that is affinity constants in the range of 10¹⁰ mol/L^–1, which respectively, reacted with the 9–18 portion and the 32–36 portion of hNPY were used in the immunoradiometric system. The assay was highly specific, NPY-related peptides such as pancreatic polypeptide and peptide YY not being detected. The lower limit of sensitivity was 0.5 pmol/L. In 303 normal subjects, plasma NPY concentrations were less than 0.5 pmol/L in 67%, 0.5 to 5.0 pmol/L in 25%, and 5.1 to 30 pmol/L in the remaining 8%. A value of 7.5 pmol/L (95th percentile value in the normal group) was considered as the upper limit of normal. Among 111 patients with various neuroendocrine tumors, elevated plasma NPY concentrations were found in patients with pheochromocytomas and neuroblastomas, the highest plasma levels being found in patients with malignant pheochromocytomas. We conclude that patients with neuroendocrine tumors, especially secreting and or malignant tumors of the sympathochromaffin system, often have elevated plasma NPY concentrations. (J Clin Endocrinol Metab 64: 808, 1989)

Received June 6, 1988.

This article has been cited by other articles:

				K. Abid, B. Rochat, P.-G. Lassahn, R. Stocklin, S. Michalet, N. Brakch, J.-F. Aubert, B. Vatansever, P. Tella, I. De Meester, et al. Kinetic Study of Neuropeptide Y (NPY) Proteolysis in Blood and Identification of NPY3-35: A NEW PEPTIDE GENERATED BY PLASMA KALLIKREIN J. Biol. Chem., September 11, 2009; 284(37): 24715 - 24724. [Abstract] [Full Text] [PDF]

				S. Cleary, J. K Phillips, T.-T. Huynh, K. Pacak, A. G Elkahloun, J. Barb, R. A Worrell, D. S Goldstein, and G. Eisenhofer Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome J. Endocrinol., May 1, 2007; 193(2): 225 - 233. [Abstract] [Full Text] [PDF]

				J. Kitlinska, K. Abe, L. Kuo, J. Pons, M. Yu, L. Li, J. Tilan, L. Everhart, E. W. Lee, Z. Zukowska, et al. Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest-Derived Tumors Cancer Res., March 1, 2005; 65(5): 1719 - 1728. [Abstract] [Full Text] [PDF]